Acrivon Therapeutics (ACRV) Competitors $1.36 +0.04 (+3.03%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.39 +0.03 (+2.13%) As of 08/22/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. LFVN, CYBN, ACTU, NKTX, NVCT, BIOA, GLSI, CRDF, DERM, and CLLSShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Lifevantage (LFVN), Cybin (CYBN), Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), BioAge Labs (BIOA), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), Journey Medical (DERM), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Its Competitors Lifevantage Cybin Actuate Therapeutics Nkarta Nuvectis Pharma BioAge Labs Greenwich LifeSciences Cardiff Oncology Journey Medical Cellectis Acrivon Therapeutics (NASDAQ:ACRV) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Do institutionals & insiders believe in ACRV or LFVN? 71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 11.9% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 20.7% of Lifevantage shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is ACRV or LFVN more profitable? Lifevantage has a net margin of 4.12% compared to Acrivon Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 34.67% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -50.78% -46.08% Lifevantage 4.12%34.67%15.24% Which has more risk & volatility, ACRV or LFVN? Acrivon Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Lifevantage has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Which has higher valuation and earnings, ACRV or LFVN? Lifevantage has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$80.56M-$2.25-0.60Lifevantage$200.16M0.82$2.94M$0.6918.96 Does the media favor ACRV or LFVN? In the previous week, Acrivon Therapeutics had 2 more articles in the media than Lifevantage. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 2 mentions for Lifevantage. Lifevantage's average media sentiment score of 0.00 beat Acrivon Therapeutics' score of -0.40 indicating that Lifevantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lifevantage 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ACRV or LFVN? Acrivon Therapeutics currently has a consensus target price of $17.57, indicating a potential upside of 1,192.02%. Lifevantage has a consensus target price of $30.50, indicating a potential upside of 133.18%. Given Acrivon Therapeutics' higher probable upside, equities research analysts plainly believe Acrivon Therapeutics is more favorable than Lifevantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLifevantage beats Acrivon Therapeutics on 9 of the 15 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.78M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.41%4.06%P/E Ratio-0.6022.9031.3026.05Price / SalesN/A516.56387.8788.44Price / CashN/A179.1038.0259.36Price / Book0.305.939.536.60Net Income-$80.56M$31.83M$3.26B$265.65M7 Day Performance0.74%1.89%2.13%2.00%1 Month Performance-2.16%1.62%3.21%0.46%1 Year Performance-85.47%9.25%30.18%18.88% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics2.5827 of 5 stars$1.36+3.0%$17.57+1,192.0%-85.5%$42.78MN/A-0.6058LFVNLifevantage3.6984 of 5 stars$13.69+1.5%$30.50+122.8%+52.1%$169.81M$222.35M19.84260News CoveragePositive NewsUpcoming EarningsCYBNCybin2.415 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$166.55MN/A-1.5850News CoverageAnalyst RevisionACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%+3.5%$166.22MN/A0.0010News CoverageAnalyst DowngradeAnalyst RevisionNKTXNkarta2.0126 of 5 stars$2.35+0.9%$13.60+478.7%-55.5%$165.49MN/A-1.59140NVCTNuvectis Pharma3.7311 of 5 stars$6.45+0.3%$15.33+137.7%-3.2%$163.69MN/A-5.518Positive NewsBIOABioAge LabsN/A$4.52-0.7%N/AN/A$163.12M$3.86M0.00N/AGLSIGreenwich LifeSciences1.6726 of 5 stars$12.01-1.3%$39.00+224.7%-18.1%$162.69MN/A-8.833Trending NewsAnalyst ForecastAnalyst RevisionCRDFCardiff Oncology1.5834 of 5 stars$2.43-0.4%$10.10+315.6%-2.9%$162.32M$680K-2.7920DERMJourney Medical1.6496 of 5 stars$7.00+0.7%$10.83+54.8%+54.7%$161.91M$56.13M-18.4290CLLSCellectis3.4003 of 5 stars$2.90+1.8%$4.00+37.9%+20.3%$158.41M$56.30M-3.54290Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Lifevantage Competitors Cybin Competitors Actuate Therapeutics Competitors Nkarta Competitors Nuvectis Pharma Competitors BioAge Labs Competitors Greenwich LifeSciences Competitors Cardiff Oncology Competitors Journey Medical Competitors Cellectis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access